美股新聞 標題聯播 · 近 24 小時 240 則 · 24 個來源 · 最新 9/21 01:56
本站只列標題、來源、時間與原文連結,不重製內文;著作權屬原媒體與原作者。新聞稿通路(PR Newswire、Business Wire、GlobeNewswire)是公司自己發的,屬第一手;媒體是轉述。
全部 · PFE近 30 天 30 則 · 第 1 / 1 頁
- Pfizer to Share Revenue With HHS in Deal on Overseas Drug Prices
- 3 Dividend Stocks to Buy and Hold for 10 Years
- 川普稱製藥協議後全美 50 州加入醫療補助藥品定價模式All 50 States Joining Medicaid Drug Pricing Model After Pharma Deals, Trump Says
- What Would It Take For Eli Lilly Stock To Keep Climbing?
- 2 High-Yield Dividend Stocks to Buy and 1 to Avoid
- Is Johnson & Johnson Stock Expensive, Or Is STELARA Hiding The Real Price?
- 類股更新：醫療保健股午盤後走軟Sector Update: Healthcare Stocks Softer Late Afternoon
- Merck Stock Nearly Doubled Without A Change In Its Revenue Growth
- 類股更新:醫療保健股週五午後下跌Sector Update: Healthcare Stocks Decline Friday Afternoon
- 輝瑞 (PFE)，現在是什麼吸引新的關注？Pfizer (PFE), What Is Drawing Fresh Attention Now?
- Pfizer’s Dividend Yield Is Enormous. But Is the Payout Still Growing?
- 類股更新：醫療保健股午盤後走高Sector Update: Healthcare Stocks Higher Late Afternoon
- Can Volume Keep Covering Eli Lilly's Price Cuts?
- How Much Do You Really Need Invested to Replace a $130,000 Salary With Dividends?
- What Happens To AbbVie Stock If SKYRIZI Slows Down?
- Pfizer's Dividend Faces Big Questions. Here Are 3 Reasons It Should Survive.
- Tarja Stenvall 獲任命為 Bavarian Nordic 執行長Tarja Stenvall Appointed Chief Executive Officer of Bavarian Nordic
- Vaxcyte (PCVX) 在大考將至之際延攬製藥老將Vaxcyte (PCVX) Brings In Pharma Veterans As Its Big Test Nears
- Pfizer Raises 2026 Revenue Guidance to $62 Billion. Here’s What’s Behind the Beat
- Is Pfizer's New Business Big Enough To Carry The Old One?
- Should You Judge JNJ Stock Without STELARA?
- The Zacks Analyst Blog Highlights Pfizer, Novartis, Candel and Janux
- What Is Pfizer (PFE) Really Getting From Its New ADC Licensing Deal?
- SLS, IBRX, IOVA In Focus Amid Big Pharma’s Early Cancer-Asset Hunt: J&J Flags M&A ‘Sweet Spot,’ Pfizer Eyes Phase 1-2 Deals
- Medicus Pharma CEO on SkinJect and Pfizer partnership – ICYMI
- Pfizer Stock Or Zoetis: Is The Comeback Worth Paying Up For?
- Medicus Pharma secures Pfizer ADC deal, advances SkinJect and precision oncology strategy
- Jim Cramer Picks J&J (JNJ) Over Eli Lilly (LLY) and Pfizer (PFE) Among These Healthcare Stocks
- AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
- Ionis’ rare neurology drug approved; Pfizer inks an ADC deal
- Pfizer's CEO Says His Company Has a "Very Big Balance Sheet" to Do Deals. Here's the Perfect Next Acquisition Target for the Pharma Giant.
- Lexicon Pharmaceuticals vs. Pfizer: Which Drugmaker Stock Is a Better Buy in 2026?
中文標題是機器翻譯(NLLB 模型,不外送資料),專有名詞靠對照表,語意以英文原題為準。預設藏掉:選股文與自動生成站(Motley Fool、24/7 Wall St、Trefis、MarketBeat…)、加密幣、律師事務所的股東訴訟廣告、非英文、新聞稿裡的人事任命 / 出席活動 / 得獎、個人理財專欄,以及通路稿標題對不到上市公司的。個股標籤是從標題辨識的(通路標準寫法 (NASDAQ: NVDA)、公司名對照);帶「?」的是從摘要辨識、信心較低。來源等級 A / B / C 只影響精選排序,不是對媒體的評價。